Paul Tudor Jones's DGX Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 18,225 shares of Quest Diagnostics Incorporated (DGX) worth $3.57 M, representing 0.01% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 34 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in DGX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2014, adding 379,378 shares. Largest reduction occurred in Q2 2014, reducing 397,667 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Quest Diagnostics Incorporated (DGX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Quest Diagnostics Incorporated (DGX) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +15,157 | Add 494.04% | 18,225 | $195.98 |
| Q4 2025 | +3,068 | New Buy | 3,068 | $173.53 |
| Q1 2025 | -7,608 | Sold Out | 0 | $0.00 |
| Q4 2024 | +7,608 | New Buy | 7,608 | $150.86 |
| Q4 2022 | -66,310 | Sold Out | 0 | $0.00 |
| Q3 2022 | +66,310 | New Buy | 66,310 | $122.70 |
| Q2 2022 | -42,092 | Sold Out | 0 | $0.00 |
| Q1 2022 | -22,555 | Reduce 34.89% | 42,092 | $136.87 |
| Q4 2021 | +28,535 | Add 79.02% | 64,647 | $173.02 |
| Q3 2021 | -25,708 | Reduce 41.59% | 36,112 | $145.30 |
| Q2 2021 | +8,223 | Add 15.34% | 61,820 | $131.96 |
| Q1 2021 | -14,613 | Reduce 21.42% | 53,597 | $128.35 |
| Q4 2020 | +59,256 | Add 661.78% | 68,210 | $119.18 |
| Q3 2020 | +8,954 | New Buy | 8,954 | $114.47 |
| Q4 2018 | -21,857 | Sold Out | 0 | $0.00 |
| Q3 2018 | +8,406 | Add 62.49% | 21,857 | $107.93 |
| Q2 2018 | +9,475 | Add 238.30% | 13,451 | $109.95 |
| Q1 2018 | +3,976 | New Buy | 3,976 | $100.35 |
| Q4 2017 | -23,603 | Sold Out | 0 | $0.00 |
| Q3 2017 | +23,603 | New Buy | 23,603 | $93.63 |
| Q4 2016 | -6,000 | Sold Out | 0 | $0.00 |
| Q2 2016 | -786 | Reduce 11.58% | 6,000 | $81.33 |
| Q1 2016 | -3,762 | Reduce 35.67% | 6,786 | $71.47 |
| Q4 2015 | -6,812 | Reduce 39.24% | 10,548 | $71.10 |
| Q3 2015 | -408 | Reduce 2.30% | 17,360 | $61.46 |
| Q2 2015 | +3,324 | Add 23.01% | 17,768 | $72.55 |
| Q1 2015 | +4,844 | Add 50.46% | 14,444 | $76.85 |
| Q4 2014 | +9,600 | New Buy | 9,600 | $67.08 |
| Q3 2014 | -8,400 | Sold Out | 0 | $0.00 |
| Q2 2014 | -397,667 | Reduce 97.93% | 8,400 | $58.69 |
| Q1 2014 | +379,378 | Add 1421.48% | 406,067 | $57.92 |
| Q4 2013 | +23,089 | Add 641.36% | 26,689 | $53.54 |
| Q3 2013 | +3,600 | New Buy | 3,600 | $61.67 |
Paul Tudor Jones's Quest Diagnostics Incorporated Investment FAQs
Paul Tudor Jones first purchased Quest Diagnostics Incorporated (DGX) in Q3 2013, acquiring 3,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Quest Diagnostics Incorporated (DGX) for 34 quarters since Q3 2013.
Paul Tudor Jones's largest addition to Quest Diagnostics Incorporated (DGX) was in Q1 2014, adding 406,067 shares worth $23.52 M.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 18,225 shares of Quest Diagnostics Incorporated (DGX), valued at approximately $3.57 M.
As of the Q1 2026 filing, Quest Diagnostics Incorporated (DGX) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Quest Diagnostics Incorporated (DGX) was 406,067 shares, as reported at the end of Q1 2014.